Biometrics: First

Showing posts with label First. Show all posts

Nano-Bio Manufacturing Consortium Selects Wearable Sensor Patch Subsystem Project as First to Receive Funding

SAN JOSE, Calif., June 19, 2014 /PRNewswire/ -- The Nano-Bio Manufacturing Consortium (NBMC) has selected a proposal by the University of Massachusetts, Amherst, to develop a wearable sensor patch subsystem as its first project in its mission to develop human performance-monitoring electronics. The project has $450,000 in total funding. Fifty percent will come from NBMC's U.S. Air Force Research Laboratory (AFRL) funds, and the remaining 50 percent will be contributed by the winning team of UMass Amherst and its industrial partner, GE.

This project, which also includes work done by the University of Cincinnati, focuses on the integration of the most mature system subcomponents in order to provide a deliverable demonstration of a microfluidic subsystem capable of time-gated acquisition of a sweat sample, along with detection of the target biomarker Orexin-A. Orexin-A is a naturally occurring neuropeptide hormone released by the hypothalamus, and plays a crucial role in the stability of arousal and alertness. A wearable paper-based patch incorporating this technology would ideally provide valuable data regarding wearer fatigue.

"This research could have profound implications not only for military use, but for any high-stress job in which alertness and responsiveness are critical," said Scott Miller, Lab Manager for Nanostructures and Surfaces at GE Global Research. "Physical and mental fatigue can be a big issue for those who work as jet pilots, air traffic controllers, fire fighters, heavy-equipment operators, and in many other careers. It's a safety issue, and the earlier we can detect fatigue, the earlier it can be addressed. At GE, we are working to help solve this tough challenge."

Based on assessment of the challenges associated with various sensor options, the project's primary development centers on an interdigitated field effect transistor (FET) sensor. This technology has already demonstrated performance for Orexin-A detection from blood and saliva samples and offers the lowest-risk system integration. The team is also developing, as a close alternative, a radio-frequency (RF) impedance sensor that may offer higher stability and sensitivity.

According to Dr. Benjamin J. Leever, Flexible Materials & Devices Program Manager at AFRL, "Biosensors are of significant interest to the Air Force due to their exceptional sensitivity for a wide variety of molecules and biomarkers, including Orexin-A, which is the focus of the NBMC project led by UMass. Better understanding the underlying mechanisms and maturing the technology could have broad applicability beyond this particular device and could enable new capabilities that strengthen the Air Force."

The project team's technical lead is Dr. James J. Watkins from the UMass Dept. of Polymer Science and Engineering, with GE's Dr. Azar Alizadeh as alternate technical representative and Laura Rea as AFRL program manager. "UMass is known nationally and around the world for its contributions to projects that advance the status of the U.S. as a technological and economic leader," stated Dr. Watkins. "We are proud to partner with GE and the University of Cincinnati to pursue this first project for the NBMC, and look forward to reporting and demonstrating the fruits of our highly experienced team's efforts."

Malcolm Thompson, NBMC's CEO, said, "These first four funded projects, beginning with the work led by UMass, reflect innovative thinking and research methodologies that we believe have the potential to greatly impact efforts to optimize U.S. airmen's safety and effectiveness in the field, as well as to be highly valuable in non-military environments."

About NBMC
The Nano-Bio Manufacturing Consortium (NBMC) was formed by the FlexTech Alliance, for the U.S. Air Force Research Laboratory (AFRL). NBMC brings together leading scientists, engineers, and business development professionals from industry and universities to mature an integrated suite of nano-bio manufacturing technologies and transition to industrial manufacturing. To do so, NBMC operates at the confluence of emerging disciplines: nanotechnology, biotechnology, advanced (additive) manufacturing, and flexible electronics. This enables the creation of advanced sensor systems for real-time, remote monitoring of biometrics and body chemistry though biomarker analysis of body fluids for Human Performance and Health Assessment. Visit www.nbmc.org.

About GE Global Research
GE Global Research is the hub of technology development for all of GE's businesses. Our scientists and engineers redefine what's possible, drive growth for our businesses, and find answers to some of the world's toughest problems.

We innovate 24 hours a day, with sites in Niskayuna, New York; San Ramon, California; Bangalore, India; Shanghai, China; Munich, Germany; and Rio de Janeiro, Brazil.

Visit GE Global Research on the web at www.geglobalresearch.com. Connect with our technologists at www.geglobalresearch.com/blog and twitter.com/geresearch

SOURCE NBMC

PixeLINK First Camera Manufacturer to Incorporate C-Mount Varioptic Auto Focus Liquid Lenses

PixeLINK leverages Varioptic electrowetting liquid lens technology (PRNewsFoto/PixeLINK)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";OTTAWA, Ontario and LYON, France, June 13, 2014 /PRNewswire/ -- PixeLINK®, a global provider of industrial cameras for the machine vision and microscopy markets, and Varioptic (a Business Unit of Parrot), the world leader in electrowetting liquid lens solutions, today announced production of the world's first industrial cameras to include an electronic, focus-controllable liquid lens. Enabling auto focus with no moving parts, these cameras will offer low power consumption, high shock resistance, and fast focus change.

Photo - http://photos.prnewswire.com/prnh/20140612/117621

PixeLINK PL-D721, PL-D722, PL-D775, and PL-D7715 machine vision cameras now incorporate the Caspian C-39N0-16 electronic, focus-controllable C-mount lens. Leveraging Varioptic electrowetting liquid lens technology, the cameras will deliver fast, noiseless, controllable auto focus from 10 cm to infinity. With a 16mm effective focal length, the Varioptic lens will offer application-controlled and user programmable-controlled auto focus capabilities in board-level and enclosed PixeLINK cameras.

"The inclusion of cutting-edge auto focus liquid lenses into our Prometheus, Hyperion, and Titan lines of industrial cameras continues a tradition of innovation at PixeLINK," explains William Lesniowski, CEO of PixeLINK. "We are extremely proud to be the first C-Mount machine vision camera manufacturer to provide auto focus control via a liquid lens, and are excited to deliver this technology to OEMs and industrial camera users in medical, inspection, and security markets around the world."

"The availability of Varioptic compatible C-Mount cameras is key to the success of this new Caspian C product range," explains Samuel Grand, Varioptic Business Unit Director. "It will enable our customers to use an AutoFocus camera system in minutes, with no hardware or software development required."

While the typical lifespan of a mechanical lens system is a few hundred thousand cycles, liquid lenses have been tested over 100 million cycles without performance degradation. Liquid lenses can also reconfigure themselves in tens of milliseconds, making them ideal for high vibration environments and applications that require fast focus changes.

Currently integrated at select customer sites, PixeLINK's new liquid lens auto focus cameras are available for purchase directly from PixeLINK or from its network of certified channel partners. Contact PixeLINK at +1 (613) 247-1211 or visit the PixeLINK website at www.pixelink.com for further details.

About PixeLINK

PixeLINK is a global provider of custom industrial cameras for the machine vision and OEM markets. For more than 20 years, PixeLINK has designed, manufactured, and supported the hardware and software requirements for the medical, inspection, security and document scanning markets. Through its custom camera design services, PixeLINK offers reliable precision camera hardware and industry-leading software that simplifies the integration of cameras into any machine vision application. www.pixelink.com

About Varioptic

Founded in 2002 by Bruno Berge, a PhD in physics, Varioptic became a Business Unit of Parrot SA in January 2012. Varioptic develops, designs and markets electrically controlled miniature optics based on its proprietary and patented programmable liquid lens technology. The ranges of technological solutions developed by Varioptic are aimed at a number of markets in the digital camera sector (biometrics, machine vision, general consumer and medical cameras). For more information: www.varioptic.com.

About Parrot

Founded in 1994 by Henri Seydoux, Parrot creates, develops and markets technologically advanced consumer products for Smartphones and tablets. Parrot offers the most extensive range of hands-free communication systems for vehicles on the market. Its globally recognized expertise in the fields of mobile connectivity and multimedia centered on Smartphones has positioned Parrot as a key player of in-car infotainment. Additionally, Parrot designs high-end wireless multimedia products dedicated to sound, and explores new possibilities in Bluetooth Smart technology. Finally, Parrot is expanding on the UAV market with the Parrot AR.Drone, the first quadricopter piloted via Wi-Fi, and new solutions to address the UAV market for professional use. Parrot, headquartered in Paris, currently employs more than 850 people worldwide and generates the majority of its sales overseas.

For more information: www.parrot.com

Media Contact

Andrew Symes
Email
+1 613-741-9484 x102

Varioptic Contact

Sales, Media & Customer Support:

Email
+33 4 37 65 35 31

SOURCE PixeLINK

LiveScan Service Provider Binary Biometrics First to Offer One-Stop Inter-State Background Screening Service Designed for Applicants Requiring Multiple Licenses

MELBOURNE, Fla., June 9, 2014 /PRNewswire/ -- Binary Biometrics, an FBI and Florida Department of Law Enforcement approved LiveScan service provider and a leading provider of background screenings for licensed professionals is now offering a service designed to ease the burden of compliance for applicants who require licensing and background screening in multiple states. Professionals who may benefit from the new service include, but are not limited to, money transmitters, mortgage brokers, real estate agents, healthcare workers, and financial advisors. The procedure works by scanning and then reprinting one electronic fingerprint record or a scanned original hard card record and then transmitting those reprints via registered post to the appropriate agency.

Logo - http://photos.prnewswire.com/prnh/20140609/105952
Photo - http://photos.prnewswire.com/prnh/20140609/105953

This process of scanning of the original hard card and reprinting on to additional cards employs advanced, FBI certified scanning technology to convert a traditional US fingerprint card (FD-258) into an electronic fingerprint record. This electronic scan is also known as LiveScan.

Once in the system, the company's state of the art laser printers reproduce exact copies of those same fingerprint records on as many additional hard cards as the user requests. These copies may be used by an applicant for most background screenings in other jurisdictions and for different regulatory agencies.

"This new service is particularly convenient for compliance officers, mortgage brokers, real estate agents, and any professional who needs to become licensed in multiple states and does not wish to travel to each state to complete an in person LiveScan or have to wait at a police station for every new state license or screening, get their prints rolled, and mail to each individual agency with the hopes that the records are not rejected for quality. We can save companies and compliance officers from wasting a lot of money, time, and avoid unnecessary headaches with this new process. I'm really excited to see this take off!" says James Timothy White, CEO.

For more details on this new service click here or visit the company's website at http://binarybiometrics.com or Call toll free at 1-855-SCAN-MY-5 (+1-855-722-6695).

About Binary Biometrics:

Binary Biometrics is a Florida-based biometrics services company that provides identity solutions to local, state, and federal governments as well as various law enforcement agencies in the United States. The company currently has 16 mobile locations throughout the State of Florida and has plans to open up several other locations across the United States.

Contact:
James White
01001010 Biometrics D/B/A
Binary Biometrics
7777 N Wickham Rd 12-247
Melbourne, Florida
32940
1-855-SCAN-MY-5 (1-855-722-6695)
Email
http://binarybiometrics.com

SOURCE Binary Biometrics

RELATED LINKS
http://binarybiometrics.com

reade more...

BioLife Solutions Announces First Quarter 2014 Results and Provides Business Update

BOTHELL, Wash., May 8, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"), today announced financial results for the first quarter of 2014 and a business update.

Q1 2014 Financial Summary

Core, proprietary product revenue increased by 47% over the first quarter of 2013, driven by continued adoption of HypoThermosol®, CryoStor® and BloodStor® in the biobanking, drug discovery, and regenerative medicine markets. Revenues were $2.1 million in the first quarter of 2014, a decline of 4% from the first quarter of 2013 which included one-time license revenue of $0.6 million. Excluding the impact of the license revenue in 2013, revenue from product sales increased 33% in the first quarter of 2014 compared with the first quarter of 2013. Gross margin was 44% in the first quarter of 2014 compared with 52% in the prior period. Excluding the impact of the license revenue that had no corresponding cost, gross margin in the first quarter of 2013 would have been 33%, with year-over-year improvement due to the strong growth in our high margin proprietary product revenue. Operating loss was $0.4 million compared to operating income of $0.2 million in the first quarter of 2013, which included the positive impact of one time license revenue of $0.6 million. Mike Rice, BioLife's President & CEO, said, "During the first quarter, in addition to again exceeding $1 million in sales of our proprietary clinical grade biopreservation media products, we completed a transformational set of financial transactions. We have substantially improved our balance sheet by eliminating all debt and closing a $15.4 million equity raisethat we believe will provide us with growth capital. We also completed a successful uplisting to the NASDAQ Capital Market®, which we believe will generate increased interest in our stock, allow us to attract more institutional investors and improve liquidity for shareholders. We are currently using some of this capital to expand our sales and marketing teams, attend additional scientific and trade conferences, and launch new organic and externally sourced products and services."

Other Significant Achievements for the First Quarter of 2014

The United States Patent and Trademark Office issued the Company a new patent on February 4, 2014. Patent number 8,642,255, titled "MATERIALS AND METHODS FOR HYPOTHERMIC COLLECTION OF WHOLE BLOOD", includes claims related to hypothermic preservation and storage of whole blood and blood components using the Company's HypoThermosol cell and tissue storage/shipping medium. We announced that Parcell Laboratories has adopted BioLife's CryoStor clinical grade cell and tissue freeze media for use in future clinical trials of Early Lineage Adult (ELA) stem cell therapies, for which Parcell holds an exclusive worldwide license. Adaptimmune Ltd adopted the Company's CryoStor clinical grade cell and tissue freeze media for use in Adaptimmune's current phase I/II clinical trial CT Antigen TCR-Engineered T Cells for Myeloma. With this announcement, Adaptimmune joined the growing list of BioLife customers developing adoptive immunotherapies for various cancers. The cancer immunotherapy field was selected by the editors of Science magazine as the Breakthrough of the Year for 2013.Contract Manufacturing Services Update and Estimated Impact to 2014 Results

We completed manufacturing products for the most recent purchase order from our contract manufacturing services customer in April 2014. Subsequently, we were informed that this customer does not intend to issue us any significant new purchase orders. We have not received any notice of termination of the manufacturing services agreement nor any breach of performance and we believe that we have met all of the performance requirements in the manufacturing services agreement with this customer.

Since the Company expects no further significant business from this customer and to enable the broadest operating freedom, on May 8, 2014, we provided this customer with notice of termination of the manufacturing services agreement dated December 22, 2011. The agreement's termination is anticipated to be effective on or about November 5, 2014, which is 180 days after the date of our notice. The agreement bars us from manufacturing or selling any solution that is approved for clinical use related to the storage and transportation of human organs for a period of two years after termination (the "tail period"). We do not expect the tail period restriction to affect our core proprietary business or our ability to pursue other non-conflicting contract manufacturing opportunities in any way.

We expect to record revenue of approximately $0.1 million related to the remainder of the most recent purchase order in the second quarter of 2014, and no further revenue subsequent to that. Based on our historical run rate of revenue and costs, assuming this customer would have otherwise generated an additional $3 million in contract manufacturing revenue during the year ended December 31, 2014, the loss of this customer is expected to result in a reduction in gross profit of approximately $0.3 million and non-absorption of up to $0.7 million in certain manufacturing overhead costs for the year ending December 31, 2014. The financial effect on the Company of this contract termination may be mitigated if the related overhead costs can be reduced or reallocated to other products, such as our existing or new core products or new contract manufacturing relationships. In contrast, we expect an increase in overall gross margin percentage related to products reflecting the reduction in materials and supplies required to manufacture the contract manufactured product.

Mike Rice commented by stating, "The contract manufacturing relationship with this customer has been a great opportunity for BioLife to utilize the excess manufacturing capacities of our best-in-class Bothell cGMP production facility. While we will continue to pursue new contract manufacturing opportunities as an important component of our business, the primary strategic focus of our resources will be to support of expansion of our core business, such as the successful launch of biologistexSM, our new cloud-based information service for controlled temperature containers for cells and tissues together with SAVSU Technologies, Inc. ("SAVSU") We are currently working with SAVSU to finalize the financial, technical and legal aspects of the biologistex product line, including whether the products will be owned and marketed by BioLife or by another entity, in which BioLife and SAVSU may hold an interest. We believe this represents a significant growth opportunity for us. biologistex is complementary with our proprietary biopreservation media products and we are now recruiting additional sales and marketing professionals to drive adoption of our entire biopreservation tools portfolio."

2014 Outlook

Management believes that awareness and adoption of the Company's products will continue to grow. In addition to the Company's NASDAQ uplisting and debt conversion which have already been achieved, specific corporate goals for 2014 include:

Proprietary, core product revenue growth in 2014 of 25%-35% over the prior year. Drive adoption of SAVSU precision thermal shippers for cells and tissues via our recently announced biologistex service. Introduction of new packaging alternatives for our biopreservation media products. Gaining additional regenerative medicine customers. Increased adoption of HypoThermosol in the hair transplantation market. The Company will host a conference call and live webcast at 4:30 p.m. ET this afternoon. To access the webcast, log on to the Investor Relations page of the BioLife Solutions website at www.biolifesolutions.com. Alternatively, you may access the live conference call by dialing (844) 825-0512 (U.S. & Canada) or (315) 625-6880 (International) with the following Conference ID: 43687830. A webcast replay will be available approximately two hours after the call and will be archived on www.biolifesolutions.com for 90 days.

About BioLife Solutions

BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions and precision thermal shipping products for cells, tissues, and organs. The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. BioLife's enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

This press release contains forward-looking statements, including, but not limited to, statements concerning our 2014 outlook, potential revenue growth and market expansion, new products and customers, the potential benefits of our NASDAQ listing, and the timing and potential consequences of the termination of our agreement with ORS and the related tail period provisions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of our products; market volatility; competition; litigation; uncertainty regarding our ability to reduce or reallocate overhead expenses related to ORS; the need to negotiate and execute definitive agreements with SAVSU Technologies, Inc., in order to proceed with the planned biologistex product line; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Senior Vice President, Chief Financial Officer

Three Month Period Ended March 31,

Amortization of deferred financing costs

Basic and diluted net loss per common share

Basic and diluted weighted average common shares used to calculate net loss per common share

Promissory notes payable, related parties

Accrued interest, related parties

Total shareholders' equity (deficiency)

Three Months Ended

March 31,

Cash used in operating activities

Cash used in investing activities

Cash provided by financing activities

Net increase (decrease) in cash and equivalents

SOURCE BioLife Solutions, Inc.

RELATED LINKS
http://www.biolifesolutions.com

reade more...

OptiScan Biomedical Enrolls First Patient in Pivotal U.S. Clinical Study of OptiScanner® 5000

HAYWARD, Calif., April 28, 2014 /PRNewswire/ -- OptiScan Biomedical Corporation, a developer of innovative continuous monitoring systems for use in the intensive care unit (ICU), today announced the enrollment of the first patient in a pivotal, multi-center Investigational Device Exemption (IDE) clinical study of the OptiScanner® 5000. The OptiScanner 5000 is the company's first-of-its-kind automated, bedside glucose monitoring system that provides physicians with critical information to manage patient glucose levels in the ICU.

The pivotal trial, known as the MANAGE IDE Study (Manual vs. Automated moNitoring Accuracy of GlucosE IDE), is expected to enroll 200 patients at up to 10 sites, most of which will be located in the U.S. The study's initial three clinical sites include: Washington University School of Medicine in St. Louis, MO; Tufts University School of Medicine in Boston, MA; and Saint Luke's Mid-America Heart Institute in Kansas City, MO. If successful, the MANAGE IDE study will serve as the basis for an application for approval in the U.S.

The OptiScanner 5000 represents a significant advancement in the delivery of care to ICU patients by automating the measurement of patients' plasma glucose, as opposed to current manual measurement of glucose in whole blood. It is estimated that approximately 20 percent of ICU patients have pre-existing diabetes and an additional 40 to 60 percent of ICU patients suffer from "stress hyperglycemia" or a temporary elevation of glucose levels, with all of these patients requiring accurate glucose monitoring to maintain glycemic control.

"The initiation of this pivotal study of the OptiScanner 5000 represents a key milestone for OptiScan as we continue our efforts to bring the paradigm-shifting potential of this platform to critically ill patients and those ICU physicians responsible for their care," said Peter Rule, chairman and chief executive officer of OptiScan Biomedical. "There is an acute need for breakthrough technologies that enable the automated, real-time monitoring of blood glucose in ICU patients in order to combat both the hyperglycemia and hypoglycemia that further complicate their already challenging health conditions. Our extensive clinical research to date demonstrates the OptiScanner 5000's ability to safely and effectively meet these needs and we are eager to see the MANAGE IDE trial further corroborate those findings."

This pivotal MANAGE IDE study follows OptiScan's previously completed MANAGE I and MANAGE II trials, which were conducted at two world class European research centers and evaluated the OptiScanner 5000 in very sick ICU patients. Taken together, these studies represent the most comprehensive clinical validation program conducted to date with a continuous blood monitoring platform in the critical care setting. Results from these studies demonstrated the ability of the OptiScanner 5000 to combine accurate blood glucose measurement with the convenience of continuous, real-time bedside monitoring.

Based on previous studies, the OptiScanner 5000 has received CE Mark certification for use in the European Union, allowing it to be sold and marketed in the 30 countries that make up the European Economic Area (EEA). OptiScan has initiated commercial efforts in the EU in 2014.

About the OptiScanner® 5000

The OptiScanner® 5000 is a first-of-its-kind automated, bedside glucose monitoring system that provides physicians with information on glucose levels in the ICU. Through automated monitoring of a patient's glucose values in plasma (as opposed to whole blood), the OptiScanner has alarms to alert clinicians to the existence of hyperglycemia (values that are too high) and hypoglycemia (values that are too low). It is estimated that between 60-80% of all ICU patients suffer from elevated glucose values, requiring insulin delivery and frequent glucose monitoring.

About OptiScan Biomedical

OptiScan Biomedical is the world leader in developing innovative continuous monitoring systems for use in hospital intensive care units (ICU). The company has developed the OptiScanner® 5000, a first-of-its-kind automated, bedside glucose monitoring system that provides accurate, automated monitoring of patients' glucose levels measured in plasma, as opposed to whole blood. The system prominently displays glucose level trend data updated every 15 minutes to help manage patients' glucose levels within an optimum target range.

The company is currently developing a next-generation OptiScanner product. The OptiScanner 6000 will expand the glucose monitoring capability of the platform technology to include monitoring of two leading measures of cardiac output and oxygenation (hemoglobin and ScvO2) in the same single blood sample, thereby providing additional information about the condition of a critically ill patient.

For more information visit: www.optiscancorp.com

Vida Strategic Partners (On behalf of OptiScan)

Patrick Nugent, Chief Financial Officer

SOURCE OptiScan Biomedical Corporation

RELATED LINKS
http://www.optiscancorp.com/

reade more...

NexID First To Offer "Liveness Detection" Software For Mobile Devices

WASHINGTON, March 18, 2014 /PRNewswire/ -- As mobile device manufacturers embed fingerprint ID into millions of smartphones, NexID Biometrics today introduces its Mobile Live Finger Detection (LFD) software, the first liveness detection solution designed specifically to exceed the convenience and security needs of mobile users worldwide. The software provides authentication rates as high as 94-97 percent, offering the highest levels of "spoof-proofing" software available on the market today.

NexID developed the Mobile LFD software solution specifically for mobile devices. Due to the variety of fingerprint-scanning solutions on the market, the company designed the software to be technology agnostic so it could work with all fingerprint sensors and mobile devices, while achieving fast execution times and resource efficiency.

The Mobile LFD software resides in a mobile device and detects whether an image captured by the device's fingerprint sensor is detecting a finger from a living person or if it's a fake or "spoofed" fingerprint.

Adding live finger detection enhances the device's security and helps eliminate unlocking a phone or one of its applications that may contain confidential information. As evidenced with Apple's iPhone 5S TouchID, fingerprint sensors are actually highly vulnerable to hacking without some form of liveness detection.

NexID will introduce Mobile LFD here this week in Booth #202 at the Connect: ID Expo, where company executives will discuss and illustrate fingerprint spoofing techniques and fake finger detection. Additionally, Clarkson University professor and NexID co-owner, Dr. Stephanie Schuckers, will be speaking at the conference at 1:50 p.m. today on the topic of "Fake Fingers and Stolen Templates: Topics in Biometric Security."

"Two of the world's leading mobile device makers now include fingerprint identification on their devices, so it doesn't take a crystal ball to see that trend continuing," said NexID COO Mark Cornett. "We believe every mobile device will incorporate some type of fingerprint ID functionality in the next couple of years. And with people relying more and more on their devices, the security of personal, financial, health and business information is not just needed, it's imperative. "

For example, businesses contemplating adopting Bring Your Own Device (BYOD) programs face the need to ensure company information on mobile devices remains private and secure; meanwhile, employees may opt for more convenience to access phone features on the same devices. Mobile LFD offers a sliding scale of security for fingerprint ID on smartphones, allowing for a simple and flexible solution.

NexID said its Mobile LFD can immediately enhance the myriad of fingerprint ID solutions being developed by sensor manufacturers, mobile devices companies, and application developers. Fingerprint sensor companies can embed the software directly onto a sensor's chip (LFD on chip), and device manufacturers can add it to the main processor (LFD on host), all to provide customers with a convenient alternative to traditional PINs and passwords. NexID's Mobile LFD solution can also be embedded in "trust zone" or trusted execution environment chip sets.

The Mobile LFD SDK will be distributed free for evaluation, solution integration, and testing purposes. NexID also offers professional services to assist with the solution integration process. Licensing and distribution agreements are negotiated separately.

For more information on NexID Mobile LFD, please visit www.nexidbiometrics.com. A white paper on liveness detection, including examples of how the company researches and tests different "spoofing" techniques, is also available.

About NexID Biometrics
NexID Biometrics is a leading software and technology supplier to the biometric authentication industry. The company develops and licenses liveness detection software that enables fingerprint-scanning technologies to more accurately, and with greater confidence, authenticate scanned images by mitigating spoof-related risks. The company also provides testing and analysis of fingerprint scanning devices to identify existing vulnerabilities to known spoofing strategies. The company's founders represent some of the world's leading authorities on biometric spoof mitigation and liveness detection.

Logo - http://photos.prnewswire.com/prnh/20131016/SF97206LOGO

SOURCE NexID Biometrics

reade more...

Wake Up Your Brain With SunSprite: First Wearable, Solar-Powered Device And App To Accurately Track Light Exposure

CAMBRIDGE, Mass., Feb. 25, 2014 /PRNewswire/ -- GoodLux Technology, LLC has announced the launch of its first innovation, SunSprite, a device that tracks and records the amount of bright light exposure an individual receives each day. SunSprite is the first completely solar-powered device and app combination to accurately measure bright light, helping users attain the physical and mental benefits of light exposure.

SunSprite debuted on Indiegogo today, marking the official launch of the product and its crowdfunding campaign. The device is available on Indiegogo for an introductory price of $99 and the first 100 devices will be priced at $89. SunSprite is expected to ship in late Q2 2014. Following the Indiegogo availability, SunSprite will retail for $149. It will make its first public appearance at this year's SXSW (March 7–16, 2014, Austin, Tex.).

You've heard of wearables and apps for fitness, sleep and nutrition. And now there's one for an equally important health component: sunlight. For decades, scientific studies have substantiated the effectiveness of bright light as a supplement to a healthy lifestyle. Bright light successfully wakes up the brain – especially in the winter months – and makes individuals more alert, engaged and energetic. Additionally, receiving bright light during the day can improve sleep habits, helping to regulate the natural circadian rhythm that is frequently disrupted by modern, hectic lifestyles. Studies have also shown bright light can serve as an effective remedy for a variety of conditions including depression, anxiety, ADHD and Parkinson's disease.

"We are thrilled to launch SunSprite, a wearable device that combines cutting-edge technology with the latest medical science to deliver a simple-to-use experience that will improve health on a global scale," said Edward Likovich, CEO of GoodLux. "SunSprite is easy to integrate into anyone's lifestyle. By wearing it and getting daily bright light, you will feel more energized during the day and sleep better at night."

SunSprite is small and lightweight, and, using its advanced magnetic closure, users can clip it on a shirt, collar, cuff, jacket, pocket or bag strap. The user can check the device or the corresponding mobile app to see their daily progress towards their recommended amount of bright light. Additionally, users can analyze their light exposure patterns and receive coaching through the app. SunSprite, which is manufactured in the USA, connects to an iOS device by Bluetooth® Smart technology and is completely solar-powered with absolutely no cords or cables.

To view the product video or purchase SunSprite, please visit: http://igg.me/at/sunsprite.

For additional information on the product and company, please visit: www.sunsprite.com.

About GoodLux:
GoodLux Technology, LLC strives to combine the best of science with our natural environment to improve health on a global scale. The company was founded by a team of Harvard-trained scientists, doctors, engineers and entrepreneurs on a mission to re-imagine the intersection of technology and nature. Become your brightest self on Facebook and Twitter.

SOURCE GoodLux Technology, LLC

Vapor Corp. Unveils E-Cigarette Industry's First Biometric Technology

LAS VEGAS, Jan. 7, 2014 /PRNewswire/ -- from ShowStoppers @ CES 2014 – Vapor Corp. (OTCQB: VPCOD) today announced its Vapor X personalized, rechargeable vaporizer unit will become available to consumers with patent pending fingerprint lock technology in time for the 2014 holiday retail season. There will be a working prototype and early iteration of the product to try today during ShowStoppers at CES 2014, Booth # A5.

In 2013 every corner of the country weighed in on the newest options in alternative smoking devices, making it clear that traditional smoking is on its way to being replaced by "vaping." Now Vapor Corp., a leading publically traded "pure-play" company in the electronic cigarette market, is answering the question on everyone's mind: what comes next?

"The next trend in alternative smoking devices is the personalized vaporizer that incorporates the technology that we expect from our high-end tech devices. Today we are debuting the newest technology in this space," says Kevin Frija, CEO of Vapor Corp. "By incorporating this biometric user identity technology into the Vapor X personal vaporizer, the door is opened to many customizable features. The fingerprint lock security allows customers to protect their device from use by another individual and this same technology will lead to the development of additional features and controls," continues Frija. "Much like the fitness mobile app technology we have seen gain recent popularity, vaporizer users will soon be able to download their 'vaping' statistics through a corresponding mobile application in order to track exactly how often they use the device."

Vaporizers are the rechargeable, customizable, high-end cousin of the disposable electronic cigarette. The Vapor X with patent pending fingerprint lock technology will incorporate biometric technologies in order to keep the device locked and turned off unless the authorized user is present. When first purchased, the device will require an authorized user to be assigned through a fingerprint scan. Once this user is assigned, he or she is the only person who can activate the device. This will not only protect against minors being able to turn on the device, but it will deem the device useless in the case of theft.

Vapor Corp.'s Vapor X personalized, rechargeable vaporizer unit will become available with patent pending fingerprint lock technology in the second half of 2014 to consumers via online and through authorized dealers nationwide. The device will retail for between $199 and $299.

About Vapor Corp.:
Vapor Corp. (OTCQB: VPCO) a publicly traded company, is a leading U.S. based electronic cigarette company, whose brands include Fifty-One®, Krave®, VaporX®, EZ Smoker®, Alternacig®, Green Puffer®, Americig®, Fumare™, Hookah Stix® and Smoke Star®. We also design and develop private label brands for some of our distribution customers. "Electronic cigarettes" or "e-cigarettes," are battery-powered products that enable users to inhale nicotine vapor without smoke, tar, ash or carbon monoxide. Vapor's electronic cigarettes and accessories are available online, through direct response to our television advertisements and through retail locations throughout the United States. For more information on Vapor Corp. and its e-cigarette brands, please visit us at www.vapor-corp.com

SOURCE Vapor Corp.

FacialNetwork.com Announces Beta Release Of "NameTag" The First Real-Time Facial Recognition App For Google Glass

NameTag - Google Glass Facial Recognition Beta App Demonstration.jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";DOWNTOWN LAS VEGAS, Nev., Dec. 19, 2013 /PRNewswire/ -- The real world is about to become a much more connected place. Utilizing some of the most accurate facial recognition software in the world, NameTag can spot a face using Google Glass' camera, send it wirelessly to a server, compare it to millions of records and in seconds return a match complete with a name, additional photos and social media profiles.

FacialNetwork.com, the developer of NameTag, is also currently creating technology to allow the scanning of profile photos from dating sites such as PlentyOfFish.com, OkCupid.com and Match.com. The technology will allow users to scan photos against the more than 450,000 entries in the National Sex Offender Registry and other criminal databases.

"I believe that this will make online dating and offline social interactions much safer and give us a far better understanding of the people around us," said NameTag's creator Kevin Alan Tussy. "It's much easier to meet interesting new people when we can simply look at someone, see their Facebook, review their LinkedIn page or maybe even see their dating site profile. Often we were interacting with people blindly or not interacting at all. NameTag on Google Glass can change all that."

No longer will social media be limited to the screens of desktops, tablets and smartphones. With the NameTag app running on Google Glass a user can simply glance at someone nearby and instantly see that person's name, occupation and even visit their Facebook, Instagram or Twitter profiles in real-time.

Tussy explains, "People will soon be able to login to www.NameTag.ws and choose whether or not they want their name and information displayed to others. It's not about invading anyone's privacy; it's about connecting people that want to be connected. We will even allow users to have one profile that is seen during business hours and another that is only seen in social situations. NameTag can make the big, anonymous world we live in as friendly as a small town."

NameTag is currently available on Glass for Beta testers and expects its website and app to launch in Q1 2014 and hopes it can be officially available to Google Glass users as well.

"Making Real-Time Facial Recognition work on Glass hasn't been easy, but we did it. Now, the question isn't if we will support Glass; it's will Google support us?" said Tussy.

Google has announced that facial recognition will not yet be supported for Glass; undoubtedly due to pressure from privacy groups but FacialNetwork.com believes that by providing applications with such vast societal benefits, Google will eventually reconsider.

"There will be many providers of augmented reality headsets and even if facial recognition is not supported by some, I'm confident that there will be solutions for such limitations. We are not publishing any information about of our financiers or investors at this time but I will say that we are involved with some very well-respected individuals and Venture Funds," said Tussy.

Demonstration videos can be seen at http://www.youtube.com/watch?v=pVwBXr_nU9Q and http://www.youtube.com/watch?v=pbnqmBqBVIU.

Video with caption: "NameTag - Google Glass Facial Recognition Beta App Demonstration." Video available at: http://www.youtube.com/watch?v=pVwBXr_nU9Q

Contact: Jordan McGee
jordan@fierrocommunications.com
Office: (702) 385-7300
Cell: (702) 538-6117

SOURCE FacialNetwork.com

reade more...

FacialNetwork.com Announces Beta Release Of "NameTag" The First Real-Time Facial Recognition App For Google Glass

NameTag is currently available on Glass for Beta testers and expects its website and app to launch in Q1 2014 and hopes it can be officially available to Google Glass users as well.

"Making Real-Time Facial Recognition work on Glass hasn't been easy, but we did it. Now, the question isn't if we will support Glass; it's will Google support us?" said Tussy.

Demonstration videos can be seen at http://www.youtube.com/watch?v=pVwBXr_nU9Q and http://www.youtube.com/watch?v=pbnqmBqBVIU.

Video with caption: "NameTag - Google Glass Facial Recognition Beta App Demonstration." Video available at: http://www.youtube.com/watch?v=pVwBXr_nU9Q

Contact: Jordan McGee
jordan@fierrocommunications.com
Office: (702) 385-7300
Cell: (702) 538-6117

SOURCE FacialNetwork.com

reade more...

FacialNetwork.com Announces Beta Release Of "NameTag" The First Real-Time Facial Recognition App For Google Glass

NameTag is currently available on Glass for Beta testers and expects its website and app to launch in Q1 2014 and hopes it can be officially available to Google Glass users as well.

"Making Real-Time Facial Recognition work on Glass hasn't been easy, but we did it. Now, the question isn't if we will support Glass; it's will Google support us?" said Tussy.

Demonstration videos can be seen at http://www.youtube.com/watch?v=pVwBXr_nU9Q and http://www.youtube.com/watch?v=pbnqmBqBVIU.

Video with caption: "NameTag - Google Glass Facial Recognition Beta App Demonstration." Video available at: http://www.youtube.com/watch?v=pVwBXr_nU9Q

Contact: Jordan McGee
jordan@fierrocommunications.com
Office: (702) 385-7300
Cell: (702) 538-6117

SOURCE FacialNetwork.com

reade more...

90 Minute DNA Results, A First Of Its Kind, Coming To Bensalem

LORTON, Va., Nov. 19, 2013 /PRNewswire/ -- The Bensalem Township Police Department, in conjunction with Bode Technology, is launching a new initiative in the field of DNA testing. This pilot program known as "BodeHITS - Rapid DNA" will be the first of its kind in the country for law enforcement.

Bensalem Township Police Department currently has its own local DNA database with over 6,000 DNA profiles consisting of evidence and reference/individual samples. Bensalem's local DNA database has been in existence since 2010 and DNA testing and analysis has played a role in over 100 criminal investigations. Many of these cases with DNA evidence were property crimes where DNA testing was traditionally not feasible.

Having a local database has guaranteed DNA analysis and results within a 30 day period. This turnaround time has led to the ability to investigate crimes much more efficiently, rather than waiting the six to nine months it would take to previously obtain DNA results. Bode Technology is located in Lorton, VA and currently maintains and analyzes all of Bensalem's DNA profiles.

The BodeHITS-Rapid DNA™ initiative will take DNA testing to the next level. This program will provide Bensalem Police the ability to have real time results with their DNA samples. The turnaround time for DNA results under this program is 90 minutes. The Rapid DNA testing implemented by Bode and enabled by Life Technologies products and services is the first of their kind in the field - in that it can test DNA evidence from a crime scene. Currently, there are several other police departments in the country evaluating rapid DNA instruments; however, those instruments are only validated for single source reference/individual samples. Additionally, those instruments only have the ability to test five samples per batch, whereas with BodeHITS - Rapid DNA, the capacity is 18 samples per batch. This rapid program is also comparing all new DNA profiles to the already existing 6,000 DNA profiles in Bensalem's local database. The goal is to generate near, real-time DNA matches to generate probable cause arrests from active criminals in active investigations.

The BodeHITS - Rapid DNA program with Bensalem is taking place at Bensalem Township Police headquarters. Bode Technology provided the services and a forensic scientist; Life Technologies, the market leader in DNA testing systems, provided 3500xL Genetic Analyzer, AmpFLSTR® Identifiler® PCR Amplification Kits and ongoing support required to perform DNA testing. Bode is also offering reach back support to review DNA HITS.

"From the streets to results in 90 minutes"

About The Bode Technology Group, Inc.

Bode operates one of the most internationally respected private DNA laboratories and provides a comprehensive set of state-of-the-art forensic DNA collection products, analysis services, and research services to law enforcement, justice system, and other government agencies around the world. Bode is one of the three wholly owned subsidiaries of SolutionPoint International, Inc.

SOURCE The Bode Technology Group, Inc.

Pages

.